Table 3.

Results of the cross-sectional analyses focusing on the interaction between the period of combination antiretroviral therapy initiation (2000–2006 and 2007–2012) and CD4⁺ cell count level at combination antiretroviral therapy initiation (<350 versus ≥350 cells/μl and <500 versus ≥500 cells/μl).

Variable	Predicted probability of achieving viral suppression in 9 months	Predicted probability of being lost to follow-up
Period and CD4+ cell count (cells/μl), median (Q1–Q3)
2000–2006 and <350	0.83 (0.70–0.84)	0.18 (0.11–0.27)
2000–2006 and ≥350	0.83 (0.62–0.87)	0.23 (0.14–0.37)
2007–2012 and <350	0.83 (0.70–0.87)	0.14 (0.09–0.22)
2007–2012 and ≥350	0.93 (0.90–0.96)	0.19 (0.12–0.26)
Period and CD4+ cell count (cells/μl), median (Q1–Q3)
2000–2006 and <500	0.78 (0.60–0.81)	0.11 (0.18–0.28)
2000–2006 and ≥500	0.70 (0.40–0.82)	0.16 (0.22–0.41)
2007–2012 and <500	0.82 (0.66–0.87)	0.09 (0.15–0.23)
2007–2012 and ≥500	0.90 (0.86–0.94)	0.13 (0.19–0.25)

Q1: 25th percentile, Q3: 75th percentile. Models were adjusted for predicted probability of achieving viral suppression in 9 months (for CD4⁺ cell count cut-off 350 cells/μl) – adherence to therapy during the first 6 months on cART, viral load at cART initiation and history of injection drug use; predicted probability of achieving viral suppression in 9 months (for CD4⁺ cell count cut-off 500 cells/μl) – sex, adherence to therapy during the first 6 months on cART, viral load at cART initiation and history of injection drug use; predicted probability of being lost to follow-up (for CD4⁺ cell count cut-off 350 cells/μl) – age, adherence to therapy during the first 12 months on cART, history of injection drug use, viral load at cART initiation and follow-up time; predicted probability of being lost to follow-up (for CD4⁺ cell count cut-off 500 cells/μl) – age, adherence to therapy during the first 12 months on cART, history of injection drug use and follow-up time.